BioCentury | Dec 4, 2020
Finance

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

Two years after its launch, precision oncology company Kinnate has become at least the twenty-second preclinical biotech to go public on NASDAQ this year, building upon a record the 2020 IPO class broke...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Neuraly’s GLP-1R agonist NLY01 for ocular hypertension

DISEASE CATEGORY: Ophthalmic disease INDICATION: Ocular hypertension Penn researchers showed that NLY01 from Neuraly Inc., could treat ocular hypertension. In mice modelling ocular hypertension, the pegylated exenatide reduced retinal ganglion cell death and mRNA levels of...
BioCentury | Dec 1, 2020
Product Development

Moderna moves & Immunocore breaks through: a BioCentury podcast

After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so participants who received a placebo can be...
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more complex, highly prevalent settings. On Thursday, Syncona Ltd. (LSE:SYNC) launched its sixth...
BioCentury | Nov 19, 2020
Finance

With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals

Two years after Clarus’ acquisition by Blackstone, the life sciences investor is taking advantage of its parent company’s scale to stretch beyond its initial sweet spot. The firm that specialized in risk-sharing deals is now...
BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

Roche, Lead Pharma form immunology partnershipDutch biotech Lead Pharma Holding B.V. will collaborate with Roche (SIX:ROG; OTCQX:RHHBY) to develop preclinical small molecules against a single, undisclosed target to treat immune-mediated diseases. Lead will receive €10 million...
BioCentury | Nov 14, 2020
Product Development

Complete response for Sanofi’s rare anemia candidate; plus Sumitovant-Urovant, C4-Roche, IN8bio and Synendos

Setback for Sanofi rare anemia therapySanofi (Euronext:SAN; NASDAQ:SNY) said late Friday that FDA issued a complete response letter to a BLA for anti-C1s mAb sutimlimab to treat hemolysis in adults with cold agglutinin disease, a rare anemia....
BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

Cross-border biotech Kira is developing therapeutics for complement-mediated cancer and inflammatory and autoimmune diseases that address the mechanistic and PK challenges of targeting the complement pathway.  Kira Pharmaceuticals Ltd. was founded in 2017 by Chairman, President...
BioCentury | Nov 12, 2020
Product Development

Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

The first interim Phase III readout for Sputnik V suggests the Russian COVID-19 vaccine and BNT162b2 from BioNTech and Pfizer have similar efficacies as an interim analysis that will reveal whether Moderna...
BioCentury | Nov 3, 2020
Finance

Nov. 3 Quick Takes: JW lists in Hong Kong; plus Fountain Healthcare’s €125M fund, and EMA reviewing GenSight, Vifor/ChemoCentryx programs

JW makes public debut on Hong Kong exchangeIn its first day of trading Tuesday, JW Therapeutics Co. Ltd. (HKEX:2126) fell HK$1.80 to HK$22 after raising HK$2.3 billion ($300 million) in an IPO. Bristol Myers Squibb...
Items per page:
1 - 10 of 2513